よむ、つかう、まなぶ。
65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版） (20 ページ)
出典
| 公開元URL | |
| 出典情報 | 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版）（9／30）《日本呼吸器学会》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
before the COVID-19 pandemic in Japan. Int J Infect Dis. 2024;143:1070
24.
9. Jackson LA, et al. Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine compared to a 23-valent pneumococcal
polysaccharide vaccine in pneumococcal vaccine naive adults. Vaccine.
2013;31:3577–84.
10.Jackson LA, et al. Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine in adults 70 years of age and older
previously vaccinated with 23-valent pneumococcal polysaccharide
vaccine. Vaccine. 2013;31:3585–93.
11.Namkoong H, et al. Comparison of the immunogenicity and safety between
polysaccharide and protein-conjugated pneumococcal vaccines among the
elderly aged 80 years or older in Japan: An open-labeled randomized
study. Vaccine. 2015;33:327-32.
12.Bonten MJ, et al. Polysaccharide conjugate vaccine against
pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114-25.
13.Suaya JA, et al. Post hoc analysis of the efficacy of the 13-valent
pneumococcal conjugate vaccine against vaccine-type community-acquired
pneumonia in at-risk older adults. Vaccine. 2018:1477-83.
14.Patterson S, et al. A post hoc assessment of duration of protection in
CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)
Trials in Vaccinol 2016;5:92-96
15.Platt HL, et al. A phase 3 trial of safety, tolerability, and
immunogenicity of V114, 15-valent pneumococcal conjugate vaccine,
compared with 13-valent pneumococcal conjugate vaccine in adults 50
years of age and older (PNEU-AGE). Vaccine. 2022;40:162-72.
16.Kishino H, et al. Safety and immunogenicity of V114, a 15-valent
pneumococcal conjugate vaccine, compared with 13-valent pneumococcal
20
24.
9. Jackson LA, et al. Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine compared to a 23-valent pneumococcal
polysaccharide vaccine in pneumococcal vaccine naive adults. Vaccine.
2013;31:3577–84.
10.Jackson LA, et al. Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine in adults 70 years of age and older
previously vaccinated with 23-valent pneumococcal polysaccharide
vaccine. Vaccine. 2013;31:3585–93.
11.Namkoong H, et al. Comparison of the immunogenicity and safety between
polysaccharide and protein-conjugated pneumococcal vaccines among the
elderly aged 80 years or older in Japan: An open-labeled randomized
study. Vaccine. 2015;33:327-32.
12.Bonten MJ, et al. Polysaccharide conjugate vaccine against
pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114-25.
13.Suaya JA, et al. Post hoc analysis of the efficacy of the 13-valent
pneumococcal conjugate vaccine against vaccine-type community-acquired
pneumonia in at-risk older adults. Vaccine. 2018:1477-83.
14.Patterson S, et al. A post hoc assessment of duration of protection in
CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)
Trials in Vaccinol 2016;5:92-96
15.Platt HL, et al. A phase 3 trial of safety, tolerability, and
immunogenicity of V114, 15-valent pneumococcal conjugate vaccine,
compared with 13-valent pneumococcal conjugate vaccine in adults 50
years of age and older (PNEU-AGE). Vaccine. 2022;40:162-72.
16.Kishino H, et al. Safety and immunogenicity of V114, a 15-valent
pneumococcal conjugate vaccine, compared with 13-valent pneumococcal
20